



# Canadian Feedlot Antimicrobial Use and Antimicrobial Resistance Surveillance Program

World Antimicrobial Resistance  
Awareness Week

November 19, 2024

Lead: **Dr. Sheryl Gow**, BSc., DVM, PhD

Team Members:

Dana Ramsay, BSc., MPH, PhD (candidate)

Alyssa Butters DVM, PhD (candidate)

Tara Funk, DVM, MVetSc, PhD (candidate)

Kayla Strong BSc., M.A., PhD



# Objectives



Provide representative national estimates of AMU and AMR in Canadian finishing feedlots





Monitor trends in AMU and AMR in feedlots over time and in the context of changes to veterinary practice




Assess the potential risk arising from AMU in feedlots on the effectiveness of antimicrobials in animals and humans

# Data collection framework



# Target population and sampling frame



## Target:

Cattle destined for slaughter in finishing feedlots in AB, SK, ON

## Strategy:

Five large feedlot veterinary consulting groups were engaged to recruit participating feedlots


## Inclusion criteria:

- Engaged in finishing phase of production
- One-time capacity >1000 animals
- Valid veterinary-client-patient relationship with the enrolling veterinarian

# AMR: FECAL ORGANISMS

## 2023 HIGHLIGHTS AND 5-YEAR TEMPORAL TRENDS

# Sample collection: fecal organisms (2023)




\**E. faecalis* and *E. faecium* were selected due to their importance in human illness. *E. hirae* was selected because it is the most common species in fed cattle.

# Recovery of fecal organisms, 2019-2023

- Stable recovery for *E. coli* and *Enterococcus* spp.
- Variable recovery for *Salmonella* and *Campylobacter*
  - ↑ in *Salmonella* spp. recovery in 2023 vs. 2022
  - ↓ in *Campylobacter* spp. recovery in 2023 vs. 2022

Province/ region	Year	Percentage (%) of isolates recovered (number of isolates recovered/number of samples submitted)							
		<i>Escherichia coli</i>		<i>Salmonella</i> spp.		<i>Campylobacter</i> spp.		<i>Enterococcus</i> spp.	
National	2019	<b>99.2%</b>	363/366	<b>7.1%</b>	26/366	<b>44.3%</b>	162/366	<b>100.0%</b>	355/355
	2020	<b>97.5%</b>	384/394	<b>3.8%</b>	15/394	<b>23.4%</b>	92/394	<b>97.5%</b>	384/394
	2021	<b>99.0%</b>	381/385	<b>4.4%</b>	17/385	<b>64.2%</b>	247/385	<b>99.0%</b>	386/390
	2022	<b>99.0%</b>	308/311	<b>2.9%</b>	9/311	<b>59.2%</b>	184/311	<b>99.4%</b>	309/311
	2023	<b>98.8%</b>	324/328	<b>4.9%</b>	16/328	<b>45.4%</b>	149/328	<b>100.0%</b>	329/329

# *E. coli* resistance is low/stable except for tetracycline, 2019-2023



- ↑ in TET resistance since 2019 (48% to 62%)
- ↑ in CIP and NAL resistance since 2019 (<1% to 2%)
- 1 isolate resistant to 6 classes, including CIP + CRO
  - AMP-AZM-CHL-CIP-CRO-SSS-SXT-TET



# Six multidrug resistant (\*MDR) *Salmonella* spp. isolates detected in 2023


Serovar	Number (%) of isolates	Number of isolates by number of antimicrobial classes in the resistance pattern				
		0	1	2-3	4-5	6-7
Give	6 (37.5)	4			1	1
Muenchen	4 (25.0)		1	3		
Typhimurium	4 (25.0)				4	
Agona	1 (6.3)	1				
Uganda	1 (6.3)			1		
<b>Total</b>	<b>16 (100)</b>	<b>5</b>	<b>1</b>	<b>4</b>	<b>5</b>	<b>1</b>

- **4** *S. Typhimurium* isolates from 2 feedlots
  - AMC-AMP-CHL-CRO-FOX-SSS-TET-
- **6** *S. Give* isolates from 4 feedlots
  - 4 susceptible
  - 2 MDR isolates (same feedlot)
  - AMC-AMP-CHL-CIP-CRO-FOX-(GEN)-NAL-SSS-TET


\*MDR indicates resistance to 3 or more antimicrobial classes

# Ciprofloxacin-resistant *Campylobacter* spp. continues to increase; gentamicin resistance detected

## *C. coli* (n = 116 in 2023)




## *C. jejuni* (n = 33 in 2023)



***C. coli***: ↑ in CIP resistance since 2019 (31% to 53%); ↓ in AZM resistance since 2019 (29% to 11%)

## High levels of resistance to select classes in *Enterococcus* spp., increase in quinupristin-dalfopristin resistance since 2019

- ↑ in QDA resistance since 2019 (13% to 35%)
- Category I resistance
  - CIP
    - 23% of *E. faecium* isolates
    - 2% of total isolates
  - LNZ
    - 1 resistant *E. faecalis* isolate
  - No vancomycin resistance




## Multidrug resistance is common in *Enterococcus* spp. (<10% of isolates are pan-susceptible in 2023)

- **9** isolates resistant to 6 classes of antimicrobials
  - 7 *E. hirae* isolates from 6 feedlots
    - DAP-ERY-LIN-QDA-STR-TET-TYL (n = 5)
  - 2 *E. faecium* isolates from 2 feedlots
    - CHL-CIP-ERY-LIN-QDA-TET-TYL
    - ERY-LIN-NIT-QDA-TET-TIG-TYL

Species	Number (%) of isolates	Number of isolates by number of antimicrobial classes in the resistance pattern				
		0	1	2-5	6-9	10-13 <sup>a</sup>
<i>Enterococcus hirae</i>	227 (69.0)		6	214	7	
<i>Enterococcus faecalis</i>	47 (14.3)	26	8	13		
<i>Enterococcus faecium</i>	31 (9.4)	2	5	22	2	
<i>Enterococcus durans</i>	8 (2.4)			8		
<i>Enterococcus casseliflavus</i>	6 (1.8)		2	4		
<i>Enterococcus avium</i>	4 (1.2)		2	2		
<i>Enterococcus malodoratus</i>	2 (0.6)		1	1		
<i>Enterococcus thailandicus</i>	2 (0.6)			2		
Unspecified <i>Enterococcus</i> spp.	2 (0.6)		1	1		
<b>Total</b>	<b>329 (100)</b>	<b>28</b>	<b>25</b>	<b>267</b>	<b>9</b>	

# Trends in key phenotypes, fecal organisms (2016-2023)



- ***Campylobacter spp.***
  - Equal percentages of MDR and pan-susceptible isolates in 2023
- ***Enterococcus spp.***
  - High percentage of MDR isolates, low percentage of pan-susceptible isolates
- ***E. coli***
  - Percentage of both MDR and pan-susceptible isolates trending downward

# Key take-home messages, AMR in fecal organisms

- **AMR in *E. coli* is relatively stable over time**
- **MDR *Salmonella* spp.**
  - 6/16 isolates (37.5%) were resistant to 4 or more classes in 2023
- **Ciprofloxacin-resistant *Campylobacter coli***
  - Significant increase in **CIP** resistance since 2019 (31% to 53%)
  - 4 **GEN**-resistant isolates from 3 feedlots in 2023
- **Streptogramin resistance in *Enterococcus* spp.**
  - Significant increase in **QDA** resistance since 2019 (13% to 35%)  
coincides with increasing use of virginiamycin in feed

# AMR: RESPIRATORY PATHOGENS

## 2023 HIGHLIGHTS AND 5-YEAR TEMPORAL TRENDS

# Sample collection: respiratory pathogens (2023)



Prairie Diagnostic Services in Saskatoon, SK

Isolation and susceptibility testing: *Mannheimia haemolytica*, *Pasteurella multocida* and *Histophilus somni*

Time point 1:  
on arrival



368 \*NP samples





One isolate of each recovered organism per sample was tested for susceptibility to a panel of 19 antimicrobials (10 classes)

Time point 2:  
at re-handling



366 NP samples




One isolate of each recovered organism per sample was tested for susceptibility to a panel of 19 antimicrobials (10 classes)

\*NP-nasopharyngeal




# Trend toward sampling younger and higher-risk cattle, 2019-2023


## BRD risk



## Age category



# Collaboration with ASSETS in 2022 impacted second sampling time



Mean DOF in 2022: **17.5**


- Temporary protocol change to reflect sampling requirements of *ASSETS* program

• Mean weight: **771 pounds**

Mean DOF in 2023: **75**

• Mean weight: **934 pounds**

# Respiratory pathogen recovery impacted by sampling protocol, 2019-2023





## Arrival

- Low recovery in 2021
  - Investigation revealed poorer recovery with increasing time between sample collection and laboratory processing
- Improved recovery with reduced times between sampling and processing in 2022 and 2023



## Rehandling

- Reduced recovery of *P. multocida* and *H. somni* in 2022 likely reflects second sampling within 3 weeks of arrival



# Increased resistance in *M. haemolytica* isolates between arrival and rehandling in 2023





Arrival




Rehandling




# Multidrug resistance detected in 55% of *P. multocida* isolates at rehandling, 2023





Arrival




Rehandling




# Increased resistance in *H. somni* isolates between arrival and rehandling in 2023




Arrival



Rehandling




# Increase in MDR at rehandling for all three BRD organisms (2019-2023 isolates combined)




# Resistance at arrival trending down, resistance at rehandling trending up for *M. haemolytica*, 2019-2023

## Arrival



## Rehandling



• **↓** in TET resistance since 2019 (18% to 3%)


• **↑** in SPT resistance since 2022 (1% to 12%)

\* Low isolate numbers increase variability, and trends prior to 2022 should be interpreted with caution




# Decreasing resistance at arrival, increasing resistance at rehandling for *P. multocida*, 2019-2023



## Arrival



## Rehandling




-  in TET, TILD + TUL resistance since 2019


-  in FLR + TET resistance since 2019
-  in ENR resistance since 2022 (6% to 12%)

# General trends toward decreased resistance at arrival, increasing resistance at rehandling for *H. somni*, 2019-2023

## Arrival



## Rehandling



•  in SPT resistance since 2019 (21% to 0%)

•  in TET + TUL resistance since 2019

\*Low isolate numbers increase variability, and trends should be interpreted with caution

## Key take-home messages, respiratory pathogens

- Trend toward sampling younger and higher-risk animals since 2019
- Recovery substantially impacted by changes to sampling protocol
- Phenotypes at arrival vs. rehandling
  - Decrease in pan-susceptibility by 32% (*MH*), 40% (*HS*) and 67% (*PM*)
  - Increase in MDR phenotype most significant for *PM* (1% at arrival → 55% at rehandling in 2023)
- Temporal trends in AMR for BRD pathogens since 2019
  - Decreased resistance at arrival over 5 years
  - Increased resistance at rehandling over 5 years

# ANTIMICROBIAL USE (AMU)

## 2023 HIGHLIGHTS AND 5-YEAR TEMPORAL TRENDS


# Sampling by Feedlot and Animals at Risk

## *Feedlot size impacts the number of cattle enrolled per feedlot*

Year	Number of Feedlots	Number of Production Lots	Animals at Risk	Average Days on Feed (DOF)
2019	23	474	135,929	203
2020	26	624	160,458	210
2021	24	598	140,984	201
2022	25	395	134,649	215
2023	26	393	129,871	199



- Targeted number of animals for AMU data collection is 150,000
  - Based on sample size calculation
  - Proportionally distributed by province and feedlot size, based on the contribution to the Canadian fed cattle population
- Participating feedlots randomly sample closed production lots annually until the required number of cattle for each feedlot is met
- The average days on feed (DOF) varied only slightly over the past five years, ranging from 199 to 215 DOF.

# Decreasing variability in DOF since 2019





- The average number of DOF has remained relatively stable since 2019.
  - Often clustered around 200 DOF.

# Cattle age and BRD risk categories mirrored each other, 2019-2023



- Distribution of calves and yearlings varied annually but was relatively equal in 2023.
- Adult cattle are uncommon in feedlots.
- The proportion of high-risk and low-risk cattle was nearly equal in 2022 and 2023.

# Roughly equal distribution of steers and heifers. Most cattle were sourced from auction market.




- **Steers and heifers** made up the majority of cattle in feedlots each year.
- The proportion of steers and heifers remained relatively constant across all five years.
- Most cattle originated from **auction markets**; however, the distribution of cattle origins varied annually.



# Health Canada's Categorization for AMU by all routes of administration

## Category I antimicrobials contribute <1% of all AMU, 2019-2023



### Category I:

- Contributes <1 mg/kg biomass
- Increased 31% since 2022 and 35% since 2019, primarily due to increased use of fluoroquinolones and third-generation cephalosporins

### Category II:


- Increased 29% since 2019, due to the introduction of streptogramins in feed.

### Category III:

- Highest use overall, driven by use of tetracyclines in feed

# Antimicrobial Use by All Routes, 2019-2023

*Tetracyclines are the major contributor to antimicrobial use*




- **Macrolides** are the second most used class of antimicrobials
- **Streptogramin** use increased annually
- Use of other antimicrobial classes remained relatively low and stable.
- The majority of AMU (95% in 2023) was driven by the administration of **in-feed antimicrobials**.


# AMU in calves often more than doubled that of yearlings

## Animal age is an important factor that can impact AMU, 2019-2023

### CALF




### YEARLING




# In-feed tetracycline AMU was more common in calves than yearlings Macrolide and streptogramin use in feed predominated in yearlings over calves

## CALF




Tetracyclines Macrolides Streptogramins

## YEARLING




Tetracyclines Macrolides Streptogramins

# Amphenicols and macrolides were the main antimicrobials used by injection for calves, while tetracyclines were more commonly administered to yearlings.




# Respiratory disease was the main reason for AMU by injection, 2019-2023



- **Lameness**-related AMU peaked in 2020 and 2021 but has declined since 2022.
- **Digestive and neurologic** conditions have remained rare reasons for AMU via injection.


## Liver abscesses and respiratory disease were the major reasons for AMU in feed, 2019-2023



- **Liver abscesses and respiratory disease (including histophilosis)** were the primary reasons for antimicrobial use in feed and are the principal drivers of AMU in beef cattle.

## Use of Medically Important Antimicrobials Versus Ionophores in Feed

*Ionophore use has remained relatively stable, 2019-2023*



■ Medically Important In-Feed Antimicrobial Use ■ Ionophore Use

- The gap between the use of ionophores and the remaining medically important antimicrobials for feedlot cattle decreased each year until 2021, but increased again in 2022 and 2023.



## Key Takeaways - AMU Comparisons

- AMU in calves (>140 mg/kg biomass) often **more than doubled** that of yearlings (<82 mg/kg biomass).
- Consistent with the **feedlot production cycle**, calves are often fed for **longer periods and have different risk factors for disease.**
- While the use of injectable antimicrobials in mg of active ingredient per kg of animal biomass was relatively stable for calves, it has increased each year for yearlings.

## Key Takeaways - AMU Comparisons

- **Tetracyclines dominated in-feed AMU**, especially in **calves** (>75%).
- Higher proportions of **macrolides** and **streptogramins** were administered in feed to **yearling cattle**.
- **Tetracyclines** made up more than 58% of the **injectable AMU** for **yearlings**, followed by macrolides and/or amphenicols, whose proportions varied year over year.
- In contrast, **amphenicols** comprised the majority of **injectable AMU** in **calves**, and predominated over the use of macrolides and tetracyclines.

# Fed Cattle Industry different than many other livestock commodities

## Key Takeaways

- Cattle entering feedlots are not uniform in terms of:
  - Age
  - Gender
  - Disease risk
  - Breed type
- Type of cattle placed in feedlots can impact:
  - Risk of disease
  - Days on feed
  - Type and quantity of AMU



# Acknowledgements

- Veterinarians and producers who make the program possible
- Funding Agencies

